Will Phase II Success of CT-388 Obesity Drug Shift Roche Holding’s (SWX:ROG) Narrative?
Roche Holding recently reported positive Phase II results for CT-388, its once-weekly dual GLP-1/GIP obesity drug candidate, showing…
Roche obesity drug CT-388 cuts weight 22.5% in Phase II
Roche (OTCQX: RHHBY) reported positive Phase II topline results for CT-388, a once-weekly…